A Phase 3 interventional study of Placebo and Vortioxetine (Lu AA21004) in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-02-11.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 11th largest by enrollment, is one of 6 that started in 2010, is one of 31 in phase 3, and was the 11th registered.
3,047 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 33 · Phase 4 13
First in 2006; this study’s year is marked. 6 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 607 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 413 across the 54 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 54 have an industry lead sponsor. The 10 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
36 studies in Depressive Disorder, Major by H. Lundbeck A/S: none open now, none under way, none of them phase 3. Of 36 finished, 20 (56%) have results posted.
Among the 36 studies in Depressive Disorder, Major by H. Lundbeck A/S, this one is the 8th largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2010, is one of 21 in phase 3, and was the 10th registered.
H. Lundbeck A/S’s Depressive Disorder, Major studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among H. Lundbeck A/S’s 36 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy, tolerability and the safety of two fixed doses of vortioxetine in the treatment of major depressive disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: Vortioxetine (Lu AA21004)
Drug: Vortioxetine (Lu AA21004)
Active Reference
Drug: Duloxetine
capsules, daily, orally
encapsulated tablets, daily, orally
Also known as: Brintellix
encapsulated capsules, daily, orally
Also known as: Cymbalta®
Change From Baseline in MADRS Total Score After 8 Weeks of Treatment.
The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.
Time frame: Baseline and Week 8
Proportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)
Time frame: Week 8
Change in Clinical Status Using CGI-I Score at Week 8
The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment.
Time frame: Week 8
Change From Baseline in MADRS Total Score After 8 Weeks of Treatment in Patients With Baseline HAM-A Total Score ≥20
Time frame: Baseline and Week 8
Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score <=10)
Time frame: Week 8
Change From Baseline in SDS Total Score After 8 Weeks of Treatment
The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.
Time frame: Baseline and Week 8
Change From Baseline in ASEX Total Score After 8 Weeks of Treatment
The Arizona Sexual Experience Scale (ASEX) is a 5-item, patient self-rated scale that evaluates a patient's recent sexual experience. Patients are asked to assess their own experience over the last week (for example, "How strong is your sex drive?", "Are your orgasms satisfying?") and respond on a 6-point scale for each item. The ASEX is used to identify individuals with sexual dysfunction. Possible total score ranges from 5 to 30, with the higher score indicating more patient sexual dysfunction. A negative change indicates a lower sexual dysfunction.
Time frame: Baseline and Week 8
Potential Discontinuation Symptoms After Abrupt Discontinuation of Treatment With Vortioxetine
The Discontinuation-Emergent Signs and Symptoms Scale (DESS) was designed to evaluate possible effects of discontinuation of antidepressant therapy. It is a clinician-rated instrument that queries for signs and symptoms on a 43-item checklist (for example, agitation, insomnia, fatigue, and dizziness) to assess whether the item (event) is discontinuation-emergent. A new or worsened event reported after discontinuation of therapy scores 1 point on the checklist, and the DESS total score is the sum of all positive scores on the checklist. A higher score indicates more symptoms.
Time frame: Change from Week 8 in DESS total score analyzed at Week 10
Patients were selected from psychiatric settings (private practices), outpatient clinics, and inpatient hospitals.
| Milestone | Placebo | Vortioxetine 15 mg | Vortioxetine 20 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Started | 158 | 151 | 151 | 147 |
| Completed | 133 | 117 | 125 | 131 |
| Not completed | 25 | 34 | 26 | 16 |
| Withdrew: Adverse event | 7 | 10 | 17 | 7 |
| Withdrew: Lack of efficacy | 6 | 8 | 2 | 1 |
| Withdrew: Non-compliance | 0 | 1 | 0 | 1 |
| Withdrew: Protocol violation | 5 | 3 | 2 | 1 |
| Withdrew: Withdrawal of consent | 6 | 6 | 2 | 2 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 2 |
| Withdrew: Administrative or other reason | 0 | 5 | 3 | 2 |
The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.
| units on a scale | Placebo | Vortioxetine 15 mg | Vortioxetine 20 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Change From Baseline in MADRS Total Score After 8 Weeks of Treatment. | -11.70 ± 0.76 | -17.23 ± 0.79 | -18.79 ± 0.78 | -21.15 ± 0.77 |
| percentage of patients | Placebo | Vortioxetine 15 mg | Vortioxetine 20 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Proportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline) | 32 | 57 | 62 | 74 |
The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment.
| units on a scale | Placebo | Vortioxetine 15 mg | Vortioxetine 20 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Change in Clinical Status Using CGI-I Score at Week 8 | 2.86 ± 0.09 | 2.18 ± 0.09 | 1.92 ± 0.09 | 1.75 ± 0.09 |
| units on a scale | Placebo | Vortioxetine 15 mg | Vortioxetine 20 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Change From Baseline in MADRS Total Score After 8 Weeks of Treatment in Patients With Baseline HAM-A Total Score ≥20 | -12.20 ± 1.09 | -17.44 ± 1.08 | -18.62 ± 1.15 | -20.91 ± 1.10 |
| percentage of patients | Placebo | Vortioxetine 15 mg | Vortioxetine 20 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score <=10) | 19 | 35 | 38 | 54 |
The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.
| units on a scale | Placebo | Vortioxetine 15 mg | Vortioxetine 20 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Change From Baseline in SDS Total Score After 8 Weeks of Treatment | -4.46 ± 0.82 | -7.70 ± 0.89 | -8.38 ± 0.85 | -11.39 ± 0.85 |
The Arizona Sexual Experience Scale (ASEX) is a 5-item, patient self-rated scale that evaluates a patient's recent sexual experience. Patients are asked to assess their own experience over the last week (for example, "How strong is your sex drive?", "Are your orgasms satisfying?") and respond on a 6-point scale for each item. The ASEX is used to identify individuals with sexual dysfunction. Possible total score ranges from 5 to 30, with the higher score indicating more patient sexual dysfunction. A negative change indicates a lower sexual dysfunction.
| units on a scale | Placebo | Vortioxetine 15 mg | Vortioxetine 20 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Change From Baseline in ASEX Total Score After 8 Weeks of Treatment | 0.28 ± 0.42 | -0.39 ± 0.43 | -0.20 ± 0.43 | -1.25 ± 0.42 |
The Discontinuation-Emergent Signs and Symptoms Scale (DESS) was designed to evaluate possible effects of discontinuation of antidepressant therapy. It is a clinician-rated instrument that queries for signs and symptoms on a 43-item checklist (for example, agitation, insomnia, fatigue, and dizziness) to assess whether the item (event) is discontinuation-emergent. A new or worsened event reported after discontinuation of therapy scores 1 point on the checklist, and the DESS total score is the sum of all positive scores on the checklist. A higher score indicates more symptoms.
| units on a scale | Placebo | Vortioxetine 15 mg | Vortioxetine 20 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Potential Discontinuation Symptoms After Abrupt Discontinuation of Treatment With Vortioxetine | 0.15 ± 0.30 | 0.01 ± 0.31 | 0.72 ± 0.31 | 2.28 ± 0.30 |
Collected over Serious Adverse Events: 8-week double-blind treatment period and 4-week safety follow-up period Other Adverse Events: 8-week double-blind treatment period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/158 (0%) | 44/158 (27.8%) |
| Vortioxetine 15 mg | — | 0/151 (0%) | 61/151 (40.4%) |
| Vortioxetine 20 mg | — | 2/151 (1.3%) | 70/151 (46.4%) |
| Duloxetine 60 mg | — | 3/147 (2%) | 67/147 (45.6%) |
| Event | Placebo | Vortioxetine 15 mg | Vortioxetine 20 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Vaginal haemorrhageReproductive system and breast disorders | 0/110 | 0/97 | 0/91 | 1/102 |
| Intentional overdoseInjury, poisoning and procedural complications | 0/158 | 0/151 | 0/151 | 1/147 |
| Lumbar vertebral fractureInjury, poisoning and procedural complications | 0/158 | 0/151 | 0/151 | 1/147 |
| Self injurious behaviourPsychiatric disorders | 0/158 | 0/151 | 0/151 | 1/147 |
| Blood pressure decreasedInvestigations | 0/158 | 0/151 | 1/151 | 0/147 |
| DizzinessNervous system disorders | 0/158 | 0/151 | 1/151 | 0/147 |
| Intentional self-injuryPsychiatric disorders | 0/158 | 0/151 | 1/151 | 0/147 |
| Event | Placebo | Vortioxetine 15 mg | Vortioxetine 20 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 16/158 | 40/151 | 48/151 | 45/147 |
| HeadacheNervous system disorders | 12/158 | 16/151 | 19/151 | 16/147 |
| DizzinessNervous system disorders | 10/158 | 7/151 | 7/151 | 15/147 |
| Dry mouthGastrointestinal disorders | 5/158 | 5/151 | 9/151 | 14/147 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 6/158 | 5/151 | 0/151 | 11/147 |
| DiarrhoeaGastrointestinal disorders | 6/158 | 6/151 | 11/151 | 9/147 |
| FatigueGeneral disorders | 4/158 | 6/151 | 5/151 | 8/147 |
| Age, Continuous(years) | Placebo | Vortioxetine 15 mg | Vortioxetine 20 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|---|
| Mean | 48.1 ± 13.1 | 47.0 ± 14.6 | 46.2 ± 13.4 | 45.6 ± 13.6 | 46.7 ± 13.7 |
| Sex: Female, Male(Participants) | Placebo | Vortioxetine 15 mg | Vortioxetine 20 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|---|
| Female | 110 | 97 | 91 | 102 | 400 |
| Male | 48 | 54 | 60 | 45 | 207 |
| MADRS baseline total score(units on a scale) | Placebo | Vortioxetine 15 mg | Vortioxetine 20 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|---|
| Mean | 31.5 ± 3.6 | 31.8 ± 3.4 | 31.2 ± 3.4 | 31.2 ± 3.5 | 31.4 ± 3.5 |
| CGI-S baseline severity score(units on a scale) | Placebo | Vortioxetine 15 mg | Vortioxetine 20 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|---|
| Mean | 4.9 ± 0.7 | 4.9 ± 0.6 | 4.8 ± 0.7 | 4.8 ± 0.7 | 4.8 ± 0.7 |
| HAM-A baseline total score(units on a scale) | Placebo | Vortioxetine 15 mg | Vortioxetine 20 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|---|
| Mean | 20.8 ± 6.6 | 21.3 ± 6.8 | 20.4 ± 6.9 | 20.5 ± 6.7 | 20.8 ± 6.7 |
| SDS total baseline score(units on a scale) | Placebo | Vortioxetine 15 mg | Vortioxetine 20 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|---|
| Mean | 19.8 ± 6.0 | 20.6 ± 5.3 | 20.7 ± 4.8 | 20.5 ± 4.4 | 20.4 ± 5.2 |
No study locations are listed for this record.
The record gives a start of May 2010 and a primary completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2014, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine